leadf
logo-loader

Selling in May this year – think twice?

no_picture_pai.jpg

Closing Bell                                                                                                      

RegMed stocks move on news – it doesn’t take a much of the brain to realize that … you might want to hold off a little on that “sell in May and go away” this year. While the adage may carry some weight to it, the cycle gets tweaked in the first year following a presidential election.

I’ve been warning people about burn rates and development cycles … as the RegMed sector is still being viewed as “Speculative” in accord to buying opportunities. I however … remain a bit bearish for 2013 and bullish overall for 2014, but we’re still likely to see continuing flat-lines in Q2 and we haven’t even seen the full Q1 results. Stay long the sector, but continue to hedge on the downside.

In the broader market … stocks erased their early losses on the final day of the month, with all 3 major averages on track to finish higher for April, despite some weak corporate earnings and mixed economic data.

 

There were some bright spots … Harvard Bio (HBIO) was up on news of their subsidiary – HART having successfully transplanted a regenerated trachea +$0.37 or +7.79% to $5.12 – and that IPO was postpone! The big dog in the park, Mesoblast (PINK: MBLTY) closed UP +$0.83 or +2.80% to $30.48 while Dendreon (DNDN) was UP  +$0.11 or +2.39% to $4.71 – do I smell a comeback followed by Stemline (STML) +$0.30 or +2.14% to $14.34 – I am beginning to question this rising stock and wonder if the floor will drop or just decline.  Athersys (ATHX) stays UP at +$0.03 or +1.37% to $2.22 but, on NO news and Cytori (CYTX) is UP again +$0.07 or +2.55% to $2.81 – resurrection time?

Closing negative were … Shire (SHPG) DOWN -$0.6 <was $2.10> or -0.70% to $93.64, and feeling the heat of trader hits were   Osiris (OSIR) DOWN -$0.16 or -1.41% to $11.22.  Another favorite followed by NeoStem (NBS) -$0.13 or -20.63% to $0.50 – not that bad … after raising $10 M in an overnight offering. Also still taking the hit was Aastrom (ASTM) after announcing another offering -$0.016 or -2.60% to $0.599 – if this marketing road trip and monetary raise takes any longer – we will be also looking at a $0.50 offering price.

Other favorites closing – was Cytomedix (CMXI) was UP <having been DOWN> +$0.01 or +2% to $0.51 while BioTime (BTX) was DOWN -$0.16 or -4.23% to $3.62 – data bases don’t sell research products – humans do – hire a current Oracle sales director with the new CFO and or buy Mike Rice who would race barefoot to be first – from BioLife Solutions (BLFS) which closed UP +$0.01 0r +3.45% to $0.30. Even Fibrocell (FCSCD) had a good day although flat at $4.22 after a stock reverse!

 

Measuring the close – barely POSITIVE – 15 green (ups) followed by 14 red (downs) and 8 black (flats) … The CBOE Volatility Index traded below 14.

Closing Bell: The NASDAQ closed UP +21.77 (+0.66%) to 3,328.79 while the DOW was UP +21.05 (+0.14%) to 14,839.80.

Share and Enjoy:
  • Digg
  •  
  • del.icio.us
  •  
  • StumbleUpon
  •  
  • Reddit
  •  
  • Facebook
  •  
  • LinkedIn
  •  
  • TwitThis

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

4D pharma plc merges with SPAC company Longevity Acquisition Corp

4D pharma plc (LON:DDDD) CEO Duncan Peyton tells Proactive the group is to get a cash injection of US$14.6mln through a merger with Longevity Acquisition Corporation (NASDAQ:LOAC), a special purpose acquisition company. Peyton says the merger will accelerate and de-risk 4D's admission to...

3 hours, 56 minutes ago

6 min read